View Financial HealthMaking Science Group 配当と自社株買い配当金 基準チェック /26Making Science Group配当を支払う会社であり、現在の利回りは2.89%です。主要情報2.9%配当利回り-8.9%バイバック利回り総株主利回り-6.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新お知らせ • Mar 25Making Science Group, S.A. announces Annual dividend, payable on April 30, 2026Making Science Group, S.A. announced Annual dividend of EUR 0.1799 per share payable on April 30, 2026, ex-date on April 28, 2026 and record date on April 29, 2026.すべての更新を表示Recent updatesBoard Change • 16hNo independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • May 11Making Science Group, S.A., Annual General Meeting, Jun 11, 2026Making Science Group, S.A., Annual General Meeting, Jun 11, 2026. Location: lopez de hoyos 135, 3, madrid., Spainお知らせ • Mar 25Making Science Group, S.A. announces Annual dividend, payable on April 30, 2026Making Science Group, S.A. announced Annual dividend of EUR 0.1799 per share payable on April 30, 2026, ex-date on April 28, 2026 and record date on April 29, 2026.お知らせ • Feb 17Making Science Group, S.A., Annual General Meeting, Mar 18, 2026Making Science Group, S.A., Annual General Meeting, Mar 18, 2026. Location: calle lopez de hoyos 135, 3., madrid SpainBoard Change • Dec 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • May 12Making Science Group, S.A., Annual General Meeting, Jun 12, 2025Making Science Group, S.A., Annual General Meeting, Jun 12, 2025. Location: calle lopez de hoyos 135, 3., madrid Spainお知らせ • Jan 09Making Science Launches RAISING, Its New AI Technology Division to Power Marketing StrategiesMaking Science has announced the launch of RAISING, its new technology division that combines the company's business expertise with data science to develop advanced solutions based on Artificial Intelligence. This new venture aims to transform brands' marketing strategies through predictive, generative, and automated AI technologies, optimizing results throughout the entire funnel. RAISING integrates cutting-edge tools that reinforce its technology proposition. These include ad-machina, Making Science's technology that uses generative AI to automate the creation and multi-platform activation of personalized ads in real-time. The tool has proven its effectiveness on platforms such as Performance Max and Meta, achieving up to 30% more conversions compared to traditional methods. Its advanced functionalalities allow the dynamic adaptation of text, image, or video ads to market and user needs, incorporating detailed data analysis, automatic translation, and large-scale optimization, ensuring more effective and profitable campaigns, which relevant companies such as Banco Santander or MediaMarkt have already integrated into their business plans. Another key product of this new division is Gauss AI, which is designed to predict user behavior and optimize distribution, measurement, and media planning strategies. This system helps companies to identify the most relevant and profitable interactions, increasing the effectiveness of their campaigns. Trust Generative AI is positioned as a versatile and secure tool for content generation at scale, automating internal and external processes in areas such as marketing, SEO, and human resources while ensuring regulatory compliance and ultimate human control. The launch of RAISING reinforces Making Science's position as a benchmark in technological innovation applied to marketing.お知らせ • Nov 19Making Science Announces Management ChangesMaking Science has announced the appointment of Nick Waters as CEO for the UK, Northern and Central Europe. Based in London, with extensive experience in business leadership and the technology market, Waters will be responsible for driving the company’s growth and expansion across Europe. Due to take up the role in February 2025, Waters brings over 20 years of experience in international media, digital, and advertising. He joins Making Science from Ebiquity Plc, where he was Group Chief Executive Officer. Before that, he spent 10 years at Dentsu Aegis Network – latterly as Executive Chairman UK & Ireland, and 12 years at Mindshare, rising to regional CEO of Europe, Middle East, and Africa. Waters’ appointment follows the announcement of Marcus Cooper as Business Director, UK, Brad Beiter as SVP of Customer Management, and José Luis Pulpón, (ex Google) as Managing Director for Making Science, Spain. These strategic hires play a vital role in Making Science’s global expansion to ensure the delivery of cutting-edge digital transformation solutions for its clients across industries.Reported Earnings • Oct 24Second quarter 2023 earnings releasedSecond quarter 2023 results: €0.12 loss per share. Revenue: €57.0m (up 15% from 2Q 2022). Net loss: €1.03m (loss widened 35% from 2Q 2022).New Risk • Jul 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (€69.6m market cap, or US$75.4m).お知らせ • May 21Making Science Group, S.A., Annual General Meeting, Jun 17, 2024Making Science Group, S.A., Annual General Meeting, Jun 17, 2024. Location: calle lopez de hoyos 135, 3., madrid SpainNew Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€74.2m market cap, or US$80.6m).New Risk • May 16New major risk - Revenue and earnings growthEarnings have declined by 65% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€74.4m market cap, or US$80.9m).New Risk • Apr 18New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Market cap is less than US$100m (€72.8m market cap, or US$77.7m).New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€91.0m market cap, or US$97.3m).New Risk • Nov 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€79.0m market cap, or US$84.7m).New Risk • Oct 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€69.0m market cap, or US$73.0m).Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €213.4m (up 89% from FY 2021). Net loss: €4.99m (loss widened 43% from FY 2021).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €13.60, the stock trades at a trailing P/E ratio of 67x. Average trailing P/E is 19x in the Media industry in Germany. Total loss to shareholders of 45% over the past year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Sep 03Making Science Group, S.A. (BME:MAKS) acquired 51% stake in Agua3 Growth Engines.Making Science Group, S.A. (BME:MAKS) acquired 51% stake in Agua3 Growth Engines on September 2, 2021. Making Science reserves a purchase option on the remaining 49% stake in Agua3 Growth Engines. Making Science Group, S.A. (BME:MAKS) completed the acquisition of 51% stake in Agua3 Growth Engines on September 2, 2021.お知らせ • May 04Making Science Group, S.A. (BME:MAKS) acquired Ventis S.R.L. for €9.5 million.Making Science Group, S.A. (BME:MAKS) acquired Ventis S.R.L. for €9.5 million on May 3, 2021. Making Science Group, S.A. (BME:MAKS) completed the acquisition of Ventis S.R.L. on May 3, 2021.Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.9m (up 130% from FY 2019). Net income: €1.54m (up 302% from FY 2019). Profit margin: 2.6% (up from 1.5% in FY 2019). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Feb 27New 90-day high: €26.50The company is up 103% from its price of €13.05 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 17% over the same period.お知らせ • Feb 10Making Science Group, SA and its subsidiary Making Science Ltd, have acquired 100% stake in Nara Media Ltd., and 51% stake in Celsius SAS.Making Science Group, SA and its subsidiary Making Science Ltd, have acquired 100% stake in Nara Media Ltd., and 51% stake in Celsius SAS on February 8, 2021. The two companies are acquired debt free. The enterprise value agreed by Nara Media is €6.15 million and will be paid with a part in shares,another in cash and another in an earn-out. The purchase price of 51% of Celsius, SAS is €1 million down payment, 300,000 Making Science shares and an earn-out of €1.2 million. Making Science has secured a purchase option for the remaining 49% of Celsius, SAS.The two companies have generated a joint EBITDA of 1.7 million euros in 2020 Making Science Group, SA and its subsidiary Making Science Ltd, have completed the acquisition of100% stake in Nara Media Ltd., and 51% stake in Celsius SAS on February 8, 2021.Is New 90 Day High Low • Feb 10New 90-day high: €15.30The company is up 6.0% from its price of €14.40 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Media industry, which is up 18% over the same period.決済の安定と成長配当データの取得安定した配当: MS7は配当の支払いを開始したばかりなので、配当金の支払いが安定しているかどうかを判断するのは時期尚早です。増加する配当: MS7は配当の支払いを開始したばかりなので、配当金が増加するかどうかを判断するのは時期尚早です。 配当利回り対市場Making Science Group 配当利回り対市場MS7 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (MS7)2.9%市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Media)9.9%アナリスト予想 (MS7) (最長3年)n/a注目すべき配当: MS7の配当金 ( 2.89% ) はGerman市場の配当金支払者の下位 25% ( 1.52% ) よりも高くなっています。高配当: MS7の配当金 ( 2.89% ) はGerman市場の配当金支払者の上位 25% ( 4.52% ) と比較すると低いです。株主への利益配当収益カバレッジ: MS7の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: MS7は 現金配当性向 ( 6% ) が低いため、配当金の支払いはキャッシュフローによって完全にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 14:56終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Making Science Group, S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 25Making Science Group, S.A. announces Annual dividend, payable on April 30, 2026Making Science Group, S.A. announced Annual dividend of EUR 0.1799 per share payable on April 30, 2026, ex-date on April 28, 2026 and record date on April 29, 2026.
Board Change • 16hNo independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • May 11Making Science Group, S.A., Annual General Meeting, Jun 11, 2026Making Science Group, S.A., Annual General Meeting, Jun 11, 2026. Location: lopez de hoyos 135, 3, madrid., Spain
お知らせ • Mar 25Making Science Group, S.A. announces Annual dividend, payable on April 30, 2026Making Science Group, S.A. announced Annual dividend of EUR 0.1799 per share payable on April 30, 2026, ex-date on April 28, 2026 and record date on April 29, 2026.
お知らせ • Feb 17Making Science Group, S.A., Annual General Meeting, Mar 18, 2026Making Science Group, S.A., Annual General Meeting, Mar 18, 2026. Location: calle lopez de hoyos 135, 3., madrid Spain
Board Change • Dec 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • May 12Making Science Group, S.A., Annual General Meeting, Jun 12, 2025Making Science Group, S.A., Annual General Meeting, Jun 12, 2025. Location: calle lopez de hoyos 135, 3., madrid Spain
お知らせ • Jan 09Making Science Launches RAISING, Its New AI Technology Division to Power Marketing StrategiesMaking Science has announced the launch of RAISING, its new technology division that combines the company's business expertise with data science to develop advanced solutions based on Artificial Intelligence. This new venture aims to transform brands' marketing strategies through predictive, generative, and automated AI technologies, optimizing results throughout the entire funnel. RAISING integrates cutting-edge tools that reinforce its technology proposition. These include ad-machina, Making Science's technology that uses generative AI to automate the creation and multi-platform activation of personalized ads in real-time. The tool has proven its effectiveness on platforms such as Performance Max and Meta, achieving up to 30% more conversions compared to traditional methods. Its advanced functionalalities allow the dynamic adaptation of text, image, or video ads to market and user needs, incorporating detailed data analysis, automatic translation, and large-scale optimization, ensuring more effective and profitable campaigns, which relevant companies such as Banco Santander or MediaMarkt have already integrated into their business plans. Another key product of this new division is Gauss AI, which is designed to predict user behavior and optimize distribution, measurement, and media planning strategies. This system helps companies to identify the most relevant and profitable interactions, increasing the effectiveness of their campaigns. Trust Generative AI is positioned as a versatile and secure tool for content generation at scale, automating internal and external processes in areas such as marketing, SEO, and human resources while ensuring regulatory compliance and ultimate human control. The launch of RAISING reinforces Making Science's position as a benchmark in technological innovation applied to marketing.
お知らせ • Nov 19Making Science Announces Management ChangesMaking Science has announced the appointment of Nick Waters as CEO for the UK, Northern and Central Europe. Based in London, with extensive experience in business leadership and the technology market, Waters will be responsible for driving the company’s growth and expansion across Europe. Due to take up the role in February 2025, Waters brings over 20 years of experience in international media, digital, and advertising. He joins Making Science from Ebiquity Plc, where he was Group Chief Executive Officer. Before that, he spent 10 years at Dentsu Aegis Network – latterly as Executive Chairman UK & Ireland, and 12 years at Mindshare, rising to regional CEO of Europe, Middle East, and Africa. Waters’ appointment follows the announcement of Marcus Cooper as Business Director, UK, Brad Beiter as SVP of Customer Management, and José Luis Pulpón, (ex Google) as Managing Director for Making Science, Spain. These strategic hires play a vital role in Making Science’s global expansion to ensure the delivery of cutting-edge digital transformation solutions for its clients across industries.
Reported Earnings • Oct 24Second quarter 2023 earnings releasedSecond quarter 2023 results: €0.12 loss per share. Revenue: €57.0m (up 15% from 2Q 2022). Net loss: €1.03m (loss widened 35% from 2Q 2022).
New Risk • Jul 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (€69.6m market cap, or US$75.4m).
お知らせ • May 21Making Science Group, S.A., Annual General Meeting, Jun 17, 2024Making Science Group, S.A., Annual General Meeting, Jun 17, 2024. Location: calle lopez de hoyos 135, 3., madrid Spain
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€74.2m market cap, or US$80.6m).
New Risk • May 16New major risk - Revenue and earnings growthEarnings have declined by 65% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€74.4m market cap, or US$80.9m).
New Risk • Apr 18New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Market cap is less than US$100m (€72.8m market cap, or US$77.7m).
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€91.0m market cap, or US$97.3m).
New Risk • Nov 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€79.0m market cap, or US$84.7m).
New Risk • Oct 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€69.0m market cap, or US$73.0m).
Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €213.4m (up 89% from FY 2021). Net loss: €4.99m (loss widened 43% from FY 2021).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €13.60, the stock trades at a trailing P/E ratio of 67x. Average trailing P/E is 19x in the Media industry in Germany. Total loss to shareholders of 45% over the past year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Sep 03Making Science Group, S.A. (BME:MAKS) acquired 51% stake in Agua3 Growth Engines.Making Science Group, S.A. (BME:MAKS) acquired 51% stake in Agua3 Growth Engines on September 2, 2021. Making Science reserves a purchase option on the remaining 49% stake in Agua3 Growth Engines. Making Science Group, S.A. (BME:MAKS) completed the acquisition of 51% stake in Agua3 Growth Engines on September 2, 2021.
お知らせ • May 04Making Science Group, S.A. (BME:MAKS) acquired Ventis S.R.L. for €9.5 million.Making Science Group, S.A. (BME:MAKS) acquired Ventis S.R.L. for €9.5 million on May 3, 2021. Making Science Group, S.A. (BME:MAKS) completed the acquisition of Ventis S.R.L. on May 3, 2021.
Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.9m (up 130% from FY 2019). Net income: €1.54m (up 302% from FY 2019). Profit margin: 2.6% (up from 1.5% in FY 2019). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Feb 27New 90-day high: €26.50The company is up 103% from its price of €13.05 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 17% over the same period.
お知らせ • Feb 10Making Science Group, SA and its subsidiary Making Science Ltd, have acquired 100% stake in Nara Media Ltd., and 51% stake in Celsius SAS.Making Science Group, SA and its subsidiary Making Science Ltd, have acquired 100% stake in Nara Media Ltd., and 51% stake in Celsius SAS on February 8, 2021. The two companies are acquired debt free. The enterprise value agreed by Nara Media is €6.15 million and will be paid with a part in shares,another in cash and another in an earn-out. The purchase price of 51% of Celsius, SAS is €1 million down payment, 300,000 Making Science shares and an earn-out of €1.2 million. Making Science has secured a purchase option for the remaining 49% of Celsius, SAS.The two companies have generated a joint EBITDA of 1.7 million euros in 2020 Making Science Group, SA and its subsidiary Making Science Ltd, have completed the acquisition of100% stake in Nara Media Ltd., and 51% stake in Celsius SAS on February 8, 2021.
Is New 90 Day High Low • Feb 10New 90-day high: €15.30The company is up 6.0% from its price of €14.40 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Media industry, which is up 18% over the same period.